Related Experiment Video
Updated: Jan 29, 2026
08:34
A Rapid and Quantitative Fluorimetric Method for Protein-Targeting Small Molecule Drug Screening
Published on: October 16, 2015
10.5K
[New cephalosporins]
Tatiana Olarte-Luis1, Dolli Cáceres-Galíndez1, Jorge Alberto Cortés1
1Departamento de Medicina Interna, Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, Colombia.
Summary
New cephalosporins and beta-lactamase inhibitor combinations show promise against resistant bacteria. Ceftaroline, ceftazidime-avibactam, and ceftolozane-tazobactam offer effective treatment options for challenging infections.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Increasing bacterial resistance globally necessitates novel antimicrobial agents.
- Cephalosporins and beta-lactamase inhibitors represent a critical area of antimicrobial research.
Purpose of the Study:
- To review new cephalosporins and their combinations with beta-lactamase inhibitors.
- To analyze spectrum, pharmacokinetics, pharmacodynamics, and clinical data for ceftaroline, ceftazidime-avibactam, and ceftolozane-tazobactam.
Main Methods:
- Literature review of current cephalosporins and beta-lactamase inhibitor combinations.
- Data collection on antimicrobial spectrum, pharmacokinetic/pharmacodynamic profiles, and clinical studies.
Main Results:
- Ceftaroline is effective against methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
- Ceftazidime-avibactam shows efficacy in treating complicated intra-abdominal and urinary tract infections.
- Ceftolozane-tazobactam demonstrates comparable activity to ceftazidime-avibactam against Gram-negative rods and non-inferiority to meropenem in intra-abdominal infections.
Conclusions:
- Ceftaroline, ceftazidime-avibactam, and ceftolozane-tazobactam are valuable additions to the antimicrobial arsenal.
- These agents offer effective treatment strategies for infections caused by resistant bacteria.
